Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Res

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The methicillin-resistant staphylococcus aureus (MRSA) are different strains of Staphylococcus aureus, or ‘staph’ bacteria that are resistant to the antibiotic methicillin as well as to related beta-lactam antibiotics such as oxacillin, penicillin, amoxicillin, and cephalosporin. Methicillin-resistant Staphylococcus aureus (MRSA) testing is utilized to detect MRSAs and no other microbes. Nucleic acid amplification tests such as the polymerase chain reaction (PCR) can be used for direct detection of mecA, which is the most common gene mediating oxacillin resistance in staphylococci.
In the U.S. Methicillin is no longer commercially available. Therefore, the test is generally done to verify the presence of oxacillin, penicillin, amoxicillin, and cephalosporin resistance to confirm presence of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. It is prominently employed in hospitals, especially in intensive care units to inhibit MRSA from spreading to other patients. On larger levels such as community and society, the MRSA test can be employed to detect the source of an outbreak. For a national level addition, testing and research may help scientists determine the cause.
Market Dynamics
The methicillin resistant Staphylococcus aureus (MRSA) testing systems market is expected to witness significant growth during the forecast period owing to the increasing number of product launches in the market. For instance, in July 2017, F. Hoffmann-La Roche announced the CE-IVD launch of the cobas MRSA/SA nucleic acid test for use on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care. MRSA and SA are both major sources of healthcare and community associated infections. The cobas MRSA/SA test is designed to support rapid screening and surveillance of MRSA & SA for use in emergency rooms, intensive care units and STAT lab settings.
However, frequent product recalls are expected to hamper the methicillin resistant Staphylococcus aureus (MRSA) testing systems market growth during the forecast period. For instance, in August 2018, the U.S. Food and Drug Administration (FDA) reported that French diagnostics firm BioMerieux has recalled two of its antimicrobial susceptibility testing (AST) cards because of false results for some strains of methicillin-resistant Staphylococcus aureus (MRSA). BioMerieux initiated the recall in January 2018, for the VITEK 2 Gram Positive Cefoxitin Screen and VITEK 2 Gram Positive AST because false tests can lead to inappropriate treatment of MRSA infection and could cause severe health consequences.
Key features of the study:
This report provides in-depth analysis of the global methicillin resistant staphylococcus aureus (MRSA) testing systems market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global methicillin resistant staphylococcus aureus (MRSA) testing systems market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for methicillin resistant Staphylococcus aureus (MRSA) testing systems market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product:
Instruments
Reagents & Kits
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Region:
North America
By Country:
U.S.
Canada
By Product:
Instruments
Reagents & Kits
By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product:
Instruments
Reagents & Kits

By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product:
Instruments
Reagents & Kits
By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product:
Instruments
Reagents & Kits
By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product:
Instruments
Reagents & Kits
By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product:
Instruments
Reagents & Kits
By Test Type:
Immunodiagnostic Test
Molecular Diagnostic Test
By End User:
Hospitals
Diagnostic Laboratories
Academic and Research Institute

Company Profiles
F.Hoffmann-La Roche*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Becton, Dickinson and Company
Hain Lifescience GmbH
BioMérieux
3M Company
Bio-Rad Laboratories Inc.
Abacus Diagnostica
Abbott Laboratories
Puritan Medical Products
Diatherix Eurofins, LLC
Arlington Scientific Inc.
AdvanDx
Genspeed Biotech GmbH
Cepheid Inc.
Luminex Corporation
R-Biopharm AG
“*” marked represents similar segmentation in other categories in the respective section.